SPCEHIGH SIGNALFINANCIAL10-K

SPCE experienced a dramatic revenue collapse while substantially increasing share count and maintaining elevated cash burn despite cost reduction efforts.

The massive revenue decline combined with a 129% increase in outstanding shares (from 35.5M to 81.4M) suggests significant dilution and operational challenges. While the company reduced operating losses and R&D spending, the fundamental business deterioration and continued cash burn of $240M creates substantial concern about the path to profitability and future funding needs.

Comparing 2026-03-30 vs 2025-02-26View on EDGAR →
FINANCIAL ANALYSIS

SPCE's financial position deteriorated significantly with revenue falling dramatically while operating cash burn remained substantial at $240M despite some improvement. The company increased capital expenditures notably to $198M and reduced debt by $96M, but current assets declined 41% while liabilities increased, creating a tighter liquidity profile. The combination of severely reduced revenue generation and continued heavy investment spending signals ongoing challenges in the commercial spaceflight business model.

FINANCIAL STATEMENT CHANGES
Revenue
P&L
-78.1%
$7.0M→$1.5M

Revenue declined 78.1% — significant demand weakness or market share loss warrants investigation.

Capital Expenditure
Cash Flow
+62.5%
$121.9M→$198.0M

Capital expenditure jumped 62.5% — major investment cycle underway; assess returns on deployment.

R&D Expense
P&L
-47.3%
$152.7M→$80.5M

R&D spending cut 47.3% — could signal cost discipline or concerning reduction in innovation investment.

Current Assets
Balance Sheet
-40.6%
$627.9M→$372.9M

Current assets declined 40.6% — monitor working capital adequacy and short-term liquidity.

Current Liabilities
Balance Sheet
+39.5%
$150.0M→$209.3M

Current liabilities surged 39.5% — significant near-term obligations; verify ability to meet short-term debt.

Inventory
Balance Sheet
-32.2%
$24.0M→$16.3M

Inventory drawn down 32.2% — strong sell-through or deliberate destocking; watch for supply constraints.

Operating Cash Flow
Cash Flow
+31.9%
-$352.7M→-$240.1M

Operating cash flow surged 31.9% — exceptional cash generation, highest quality earnings signal.

Operating Income
P&L
+24.2%
-$376.6M→-$285.3M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

Total Debt
Balance Sheet
-22.8%
$420.1M→$324.2M

Debt reduced 22.8% — deleveraging strengthens balance sheet and reduces financial risk.

Net Income
P&L
+19.6%
-$346.7M→-$278.9M

Net income grew 19.6% — bottom-line growth signals improving overall business health.

LANGUAGE CHANGES
NEW — 2026-03-30
PRIOR — 2025-02-26
ADDED
See the definitions of large accelerated filer, accelerated filer, smaller reporting company and emerging growth company in Rule 12b-2 of the Exchange Act.
As of March 23, 2026, there were 81,408,715 shares of the registrant s common stock, $0.0001 par value per share, issued and outstanding.
Management s Discussion and Analysis of Financial Condition and Results of Operations 51 Item 7A.
Management s Discussion and Analysis of Financial Condition and Results of Operations below and for the reasons described elsewhere in this Annual Report on Form 10-K.
Although we believe that the expectations reflected in the forward-looking statements are reasonable, our information may be incomplete or limited, and we cannot guarantee future results.
Delays in the development of our next-generation spaceships would adversely impact our business, financial condition and results of operations.
Any delays in the manufacture, production and commercialization of additional spaceflight systems, including our next-generation spaceships and launch vehicles, may adversely impact our business, financial condition and results of operations.
Management has concluded that there are conditions present in the aggregate that raise substantial doubt about our ability to continue as a going concern.
Failure to comply with a wide variety of extensive and evolving government laws and regulations could have a material adverse effect on our business.
Our spaceflight system was developed using our proprietary technology and processes and is focused on providing space travel experiences for private astronauts, autonomous research flight opportunities and human-tended research flights.
REMOVED
See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.
As of February 14, 2025, there were 35,528,350 shares of the registrant's common stock, $0.0001 par value per share, issued and outstanding.
Management's Discussion and Analysis of Financial Condition and Results of Operations 47 Item 7A.
Management's Discussion and Analysis of Financial Condition and Results of Operations" below and for the reasons described elsewhere in this Annual Report on Form 10-K.
The market for commercial spaceflight has not been established with precision.
It is still emerging and may not achieve the growth potential we expect or may grow more slowly than expected.
We paused flights in mid-2024 with our initial spaceship, VSS Unity, and mothership carrier aircraft, VMS Eve, which together comprised our initial commercial spaceflight system, as we develop our next-generation spaceflight system, which includes our Delta Class spaceships and additional motherships.
Any delays in the development of our Delta Class spaceships, including successful completion of the flight test program, would adversely impact our business, financial condition and results of operations.
Our ability to grow our business depends on the successful development of our next-generation spaceflight system and related technology, which is subject to many uncertainties, some of which are beyond our control.
Any delays in the development and manufacture of additional next-generation spaceflight systems and related technology may adversely impact our business, financial condition and results of operations.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →